Holen Sie sich die Stockscreener-App
27.32
0.66%
0.18
Handel nachbörslich:
27.04
-0.28
-1.02%
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt RARE?
Forum
Prognose
Aktiensplit
Schlusskurs vom Vortag:
$27.14
Offen:
$26.95
24-Stunden-Volumen:
1.81M
Relative Volume:
1.08
Marktkapitalisierung:
$2.58B
Einnahmen:
$522.75M
Nettoeinkommen (Verlust:
$-558.99M
KGV:
-4.2226
EPS:
-6.47
Netto-Cashflow:
$-439.53M
1W Leistung:
+0.07%
1M Leistung:
-24.86%
6M Leistung:
-36.51%
1J Leistung:
-39.32%
1-Tages-Spanne:
$26.85
$27.53
1-Wochen-Bereich:
$26.85
$28.48
52-Wochen-Spanne:
$25.81
$60.37
Ultragenyx Pharmaceutical Inc Stock (RARE) Company Profile
Firmenname
Ultragenyx Pharmaceutical Inc
Sektor
Branche
Telefon
415-483-8800
Adresse
60 LEVERONI COURT, NOVATO, CA
Vergleichen Sie RARE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
RARE
Ultragenyx Pharmaceutical Inc
|
27.32 | 2.57B | 522.75M | -558.99M | -439.53M | -6.47 |
|
VRTX
Vertex Pharmaceuticals Inc
|
456.87 | 120.48B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
545.46 | 59.88B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
392.24 | 44.31B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
670.33 | 36.65B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
301.13 | 32.46B | 3.81B | -644.79M | -669.77M | -6.24 |
Ultragenyx Pharmaceutical Inc Stock (RARE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-28 | Fortgesetzt | H.C. Wainwright | Buy |
| 2025-05-28 | Eingeleitet | William Blair | Outperform |
| 2024-06-06 | Hochstufung | Goldman | Neutral → Buy |
| 2024-04-22 | Eingeleitet | RBC Capital Mkts | Outperform |
| 2023-12-08 | Eingeleitet | Wells Fargo | Overweight |
| 2023-06-14 | Fortgesetzt | Credit Suisse | Outperform |
| 2023-06-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-04-26 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-01-18 | Fortgesetzt | Canaccord Genuity | Buy |
| 2022-12-30 | Fortgesetzt | H.C. Wainwright | Buy |
| 2022-11-03 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2022-10-13 | Hochstufung | Guggenheim | Neutral → Buy |
| 2022-08-01 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-03-16 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2022-02-11 | Hochstufung | JP Morgan | Neutral → Overweight |
| 2021-09-30 | Eingeleitet | H.C. Wainwright | Buy |
| 2021-08-19 | Eingeleitet | UBS | Sell |
| 2021-07-15 | Eingeleitet | Guggenheim | Neutral |
| 2021-06-29 | Hochstufung | BofA Securities | Neutral → Buy |
| 2021-06-04 | Fortgesetzt | Robert W. Baird | Neutral |
| 2021-05-06 | Hochstufung | Citigroup | Neutral → Buy |
| 2021-05-06 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2021-04-26 | Fortgesetzt | Credit Suisse | Neutral |
| 2021-03-02 | Fortgesetzt | Stifel | Buy |
| 2021-02-12 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2020-12-07 | Herabstufung | Wedbush | Outperform → Neutral |
| 2020-11-24 | Fortgesetzt | Evercore ISI | In-line |
| 2020-11-12 | Herabstufung | BofA Securities | Buy → Neutral |
| 2019-08-02 | Fortgesetzt | Wedbush | Outperform |
| 2019-03-27 | Hochstufung | Morgan Stanley | Equal-Weight → Overweight |
| 2019-02-22 | Fortgesetzt | Raymond James | Outperform |
| 2019-01-02 | Herabstufung | Raymond James | Outperform → Mkt Perform |
| 2018-11-08 | Hochstufung | Citigroup | Sell → Neutral |
| 2018-09-10 | Eingeleitet | Morgan Stanley | Equal-Weight |
| 2018-06-21 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2018-05-11 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2018-05-10 | Eingeleitet | Goldman | Neutral |
| 2018-04-18 | Hochstufung | SunTrust | Hold → Buy |
| 2018-03-22 | Fortgesetzt | Piper Jaffray | Overweight |
| 2018-02-21 | Bestätigt | Stifel | Buy |
| 2018-01-22 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2018-01-18 | Eingeleitet | Credit Suisse | Outperform |
| 2017-12-05 | Bestätigt | Barclays | Equal Weight |
| 2017-12-04 | Hochstufung | Jefferies | Hold → Buy |
| 2017-09-14 | Hochstufung | Wedbush | Neutral → Outperform |
Alle ansehen
Ultragenyx Pharmaceutical Inc Aktie (RARE) Neueste Nachrichten
Ultragenyx Completes Enrollment for GTX-102 Phase 3 Study - TipRanks
Ultragenyx Completes Enrollment of Phase 3 Aspire Study - GlobeNewswire
Breakthrough Angelman Syndrome Drug Trial Hits Major Milestone: 129 Patients Enrolled in Record Time - Stock Titan
Ultragenyx Pharmaceutical Inc. (RARE) Gets FDA CRL for UX111, Vows Quick Resubmission - Insider Monkey
Ultragenyx to Host Conference Call for Second Quarter 2025 Financial Results and Corporate Update - GlobeNewswire
How Ultragenyx Pharmaceutical Inc. stock performs during market volatilityWeekly Chart Watchlist with Trade Guidance - Newser
Why Ultragenyx Pharmaceutical Inc. stock attracts strong analyst attentionSummary of Reliable Long-Term Trade Models - Newser
Ultragenyx Pharmaceutical Inc. stock trendline breakdownHigh Return Trade Roadmap with Setup Filters - Newser
Is Ultragenyx Pharmaceutical Inc. stock overvalued or undervaluedAI Powered Review For 2025 - jammulinksnews.com
Ultragenyx Pharmaceutical Inc. (RARE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Investors to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Why is Ultragenyx Pharmaceutical Inc. stock attracting strong analyst attentionDaily Trading Tracker For Fast Growth - jammulinksnews.com
Ultragenyx's Strategic Momentum: Catalyzing Long-Term Value Through Revenue Growth and Gene Therapy Innovation - AInvest
Ultragenyx Pharmaceutical Inc. to Host Conference Call for Q2 2025 Financial Results and Corporate Update - Quiver Quantitative
Rare Disease Leader Ultragenyx Sets Q2 2025 Earnings Call: Key Updates Expected for Genetic Disease Pipeline - Stock Titan
Ultragenyx Pharmaceutical Inc. stock momentum explainedWeekly Portfolio Update with ROI Focus - Newser
Ultragenyx Pharmaceutical Inc. Shows Early Signs of Technical StrengthTriple Digit Growth Focused Trade Plan Reviewed - beatles.ru
Ultragenyx: July Selloff Creates Buying Opportunity Ahead Of UX143 Catalyst (NASDAQ:RARE) - Seeking Alpha
Custom strategy builders for tracking Ultragenyx Pharmaceutical Inc.Free Daily Momentum Screener With Alerts - Newser
Ultragenyx Pharmaceutical (NASDAQ:RARE) Now Covered by Analysts at HC Wainwright - Defense World
Ultragenyx Represents 'Intriguing Buying Opportunity,' Despite Recent Setbacks - Benzinga
Does Ultragenyx Pharmaceutical Inc. stock perform well during market downturnsExpert guidance for superior capital growth - jammulinksnews.com
Ultragenyx Pharma stock rating initiated at Buy by H.C. Wainwright - Investing.com
What is the dividend policy of Ultragenyx Pharmaceutical Inc. stockCapitalize on proven investment strategies - jammulinksnews.com
What institutional investors are buying Ultragenyx Pharmaceutical Inc. stockCapitalize on proven investment strategies - jammulinksnews.com
How hedge fund analytics apply to Ultragenyx Pharmaceutical Inc. stockReal-Time AI Generated Market Forecast - Newser
Visual trend scoring systems applied to Ultragenyx Pharmaceutical Inc.Free Growth Focused Entry Plan Suggestions - Newser
Ultragenyx Pharmaceutical Inc. stock trendline breakdown Capital Protection Strategy With Risk Analysis - Newser
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Ultragenyx Pharmaceutical Inc.RARE - PR Newswire
What catalysts could drive Ultragenyx Pharmaceutical Inc. stock higher in 2025Free Daily Trading Room Entry - jammulinksnews.com
How does Ultragenyx Pharmaceutical Inc. compare to its industry peersMaximize your portfolio’s earning potential - jammulinksnews.com
How strong is Ultragenyx Pharmaceutical Inc. company’s balance sheetGet real-time alerts on high-potential stocks - jammulinksnews.com
New Product Launches: Will They Boost Ultragenyx Pharmaceutical Inc. Stock in 2025Top Rated Trade Entries - Newser
How Resilient Is Ultragenyx Pharmaceutical Inc. Stock During Economic DownturnsCarefully Curated High Return Stocks - Newser
Bronstein, Gewirtz & Grossman, LLC Encourages Ultragenyx Pharmaceutical Inc. (RARE) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
Will Ultragenyx Pharmaceutical Inc. stock split in the near futureTurbocharged investment results - jammulinksnews.com
What analysts say about Ultragenyx Pharmaceutical Inc. stockFree Trend-Following Techniques - Autocar Professional
Ultragenyx Pharmaceutical Inc. Stock Analysis and ForecastFree Stock Market Return Analysis - Autocar Professional
Analysts’ Opinions Are Mixed on These Healthcare Stocks: Intuitive Surgical (ISRG), Quest Diagnostics (DGX) and Ultragenyx Pharmaceutical (RARE) - The Globe and Mail
Adeno-Associated Virus (AAV) Vectors in Gene Therapy Clinical, - openPR.com
Ultragenyx Pharmaceutical Inc. (RARE) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
What drives Ultragenyx Pharmaceutical Inc. stock priceRapid portfolio appreciation - Autocar Professional
RARE ALERT: Levi & Korsinsky Investigates Ultragenyx Pharmaceutical Inc. on Behalf of Shareholders Who Lost Money - ACCESS Newswire
RARE ACTIVE INVESTIGATION: Lost Money on Ultragenyx Pharmaceutical Inc.? Contact Levi & Korsinsky Now - ACCESS Newswire
Finanzdaten der Ultragenyx Pharmaceutical Inc-Aktie (RARE)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.43%
2.00%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):